Compound class:
Synthetic organic
Comment: We obtained the chemical structure for culmerciclib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a cyclin-dependent kinase inhibitor and antineoplastic. This Chemical structure mapped to PubChem CID 122544510, and to a structure in Nanjing Mingde New Drug Research and Development Company's patent WO2016141881A1 [1] which claims selective CDK4/6 inhibitors as anticancer drugs.
|
|
References |
1. Ding Z, Chen S, Zhao B, Xu Z, Liu Y, Lin R, Wang F, Li J. (2016)
Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug. Patent number: WO2016141881A1. Assignee: Nanjing Mingde New Drug Research and Development Co. Priority date: 11/03/2015. Publication date: 15/09/2016. |